Inovio: Good News About the Firm’s COVID-19 Vaccine’s Capability and Durability


Inovio’s COVID-19 Vaccine INO-4800 Accomplished the Following:

  • Durable antibody and T cell responses in rhesus macaques for 4 months.
  • Long-term protection in non-human primates challenged with SARS-CoV-2 virus 13     weeks from vaccination. No other vaccine has demonstrated it.
  • Reduced viral loads and faster viral clearance in macaques’ lungs and nasal passages as a result of a good Memory T and B cell responses.  
  • INO-4800 vaccination generated antibodies neutralizing both the earlier strain of the virus as well as the mutant variant (D614G) that has emerged with greater infectivity and now accounts for >80% of newly circulating virus.

No antibody-dependent enhanced disease events were reported.

Leave a Reply